The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 13, 2020

Filed:

Jul. 22, 2016
Applicant:

Institute of Hematology and Blood Diseases Hospital, Cams & Pumc, Tianjin, CN;

Inventors:

Tao Cheng, Tianjin, CN;

Hui Cheng, Tianjin, CN;

Yajie Wang, Tianjin, CN;

Hongyan Zhang, Tianjin, CN;

Yawei Zheng, Tianjin, CN;

Sha Hao, Tianjin, CN;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/352 (2006.01); A61K 31/506 (2006.01); A61K 31/19 (2006.01); A61K 38/17 (2006.01); A61K 31/135 (2006.01); A61K 31/7105 (2006.01); A61K 31/711 (2006.01); A61K 31/444 (2006.01); A61K 31/137 (2006.01); A61P 35/02 (2006.01); A61K 31/192 (2006.01); A61K 31/4375 (2006.01); A61K 31/519 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/352 (2013.01); A61K 31/135 (2013.01); A61K 31/137 (2013.01); A61K 31/19 (2013.01); A61K 31/192 (2013.01); A61K 31/4375 (2013.01); A61K 31/444 (2013.01); A61K 31/506 (2013.01); A61K 31/519 (2013.01); A61K 31/711 (2013.01); A61K 31/7105 (2013.01); A61K 38/1709 (2013.01); A61K 38/1761 (2013.01); A61K 45/06 (2013.01); A61P 35/02 (2018.01);
Abstract

The present invention provides a method for treating leukemia utilizing somatic cell reprogramming. The method includes a step of introduction of somatic cell reprogramming inducing factors Oct-4, Sox-2, Klf4 and c-Myc (OSKM for short) into leukemic cells or a step of utilizing small reprogramming molecules in in-vitro culture. It promotes leukemic cells to initiate process of somatic cell reprogramming in order to induce apoptosis and finally purpose of eliminating leukemic cells in-vivo or in-vitro is achieved. It provides new ideas and methods for clinical treatment of leukemia in the future.


Find Patent Forward Citations

Loading…